Spironolactone in chronic hemodialysis patients improves cardiac function

We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate...

Full description

Bibliographic Details
Main Authors: Taheri Shahram, Mortazavi Mojhgan, Shahidi Shahrzad, Pourmoghadas Ali, Garakyaraghi Mohammad, Seirafian Shiva, Eshaghian Afrooz, Ghassami Maryam
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2009-01-01
Series:Saudi Journal of Kidney Diseases and Transplantation
Subjects:
Online Access:http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=Taheri
id doaj-e2c8af0434f3415695a7eb65ff258537
record_format Article
spelling doaj-e2c8af0434f3415695a7eb65ff2585372020-11-24T22:09:09ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422009-01-01203392397Spironolactone in chronic hemodialysis patients improves cardiac functionTaheri ShahramMortazavi MojhganShahidi ShahrzadPourmoghadas AliGarakyaraghi MohammadSeirafian ShivaEshaghian AfroozGhassami MaryamWe performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi-ronolactone after each dialysis session within six months, and the rest received a placebo. Echo-cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi-ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=TaheriEjection fraction (EF)HemodialysisHeart failureLeft ventricle (LV) massSpironolactone
collection DOAJ
language English
format Article
sources DOAJ
author Taheri Shahram
Mortazavi Mojhgan
Shahidi Shahrzad
Pourmoghadas Ali
Garakyaraghi Mohammad
Seirafian Shiva
Eshaghian Afrooz
Ghassami Maryam
spellingShingle Taheri Shahram
Mortazavi Mojhgan
Shahidi Shahrzad
Pourmoghadas Ali
Garakyaraghi Mohammad
Seirafian Shiva
Eshaghian Afrooz
Ghassami Maryam
Spironolactone in chronic hemodialysis patients improves cardiac function
Saudi Journal of Kidney Diseases and Transplantation
Ejection fraction (EF)
Hemodialysis
Heart failure
Left ventricle (LV) mass
Spironolactone
author_facet Taheri Shahram
Mortazavi Mojhgan
Shahidi Shahrzad
Pourmoghadas Ali
Garakyaraghi Mohammad
Seirafian Shiva
Eshaghian Afrooz
Ghassami Maryam
author_sort Taheri Shahram
title Spironolactone in chronic hemodialysis patients improves cardiac function
title_short Spironolactone in chronic hemodialysis patients improves cardiac function
title_full Spironolactone in chronic hemodialysis patients improves cardiac function
title_fullStr Spironolactone in chronic hemodialysis patients improves cardiac function
title_full_unstemmed Spironolactone in chronic hemodialysis patients improves cardiac function
title_sort spironolactone in chronic hemodialysis patients improves cardiac function
publisher Wolters Kluwer Medknow Publications
series Saudi Journal of Kidney Diseases and Transplantation
issn 1319-2442
publishDate 2009-01-01
description We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardio-vascular function and reduce hospitalization without inducing hyperkalemia. We enrolled 16 chro-nic HD patients with moderate to severe heart failure and left ventricle ejection fraction :5 45%. In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spi-ronolactone after each dialysis session within six months, and the rest received a placebo. Echo-cardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study. Serum potassium was measured predialysis every 4 weeks. The mean ejection fraction increased signi-ficantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs. 0.83 ± 4.9, P= 0.046). The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs. 3 ± 7.97. 95%, P= 0.021). The incidence of hyperkalemia was not significantly increased in the study or controlled groups. In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.
topic Ejection fraction (EF)
Hemodialysis
Heart failure
Left ventricle (LV) mass
Spironolactone
url http://www.sjkdt.org/article.asp?issn=1319-2442;year=2009;volume=20;issue=3;spage=392;epage=397;aulast=Taheri
work_keys_str_mv AT taherishahram spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT mortazavimojhgan spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT shahidishahrzad spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT pourmoghadasali spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT garakyaraghimohammad spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT seirafianshiva spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT eshaghianafrooz spironolactoneinchronichemodialysispatientsimprovescardiacfunction
AT ghassamimaryam spironolactoneinchronichemodialysispatientsimprovescardiacfunction
_version_ 1725813415188889600